唑来磷酸钠在绝经后骨质疏松症患者中的临床效果及对骨折率的影响研究

Clinical Effect of Zoledronic Acid on Postmenopausal Osteoporosis and Its Effect on Fracture Rate

目的:探讨唑来磷酸钠在绝经后骨质疏松症患者中的临床效果及对骨折率的影响。方法:选取2016年2月-2017年2月医院收治的绝经后骨质疏松症患者100例,按照随机数字表法分为对照组和观察组,各50例。两组均口服钙尔奇D片、骨化三醇胶丸治疗,对照组联合阿仑膦酸钠治疗,观察组联合唑来磷酸钠治疗。采用视觉模拟疼痛评分(VAS)量表对两组治疗前、后疼痛情况进行评估,采用双能X线骨密度测定仪完成腰椎1~4、股骨颈及Ward’s骨密度(BMD)测定,比较两组临床疗效及对骨折率的影响。结果:两组治疗前VAS评分比较差异无统计学意义(P>0.05);观察组治疗后1、3、6个月VAS评分均低于对照组(P<0.05);两组治疗前腰椎1~4、股骨颈及Ward’s骨密度水平比较差异均无统计学意义(P>0.05);观察组治疗后6个月腰椎1~4、股骨颈及Ward’s骨密度水平均高于对照组(P<0.05);两组治疗后1个月骨折发生率比较差异无统计学意义(P>0.05),观察组治疗后3、6个月骨折发生率均低于对照组(P<0.05)。结论:将唑来磷酸钠用于绝经后骨质疏松症患者中效果理想,有助于减轻患者疼痛,改善患者骨密度水平,降低骨折率,值得推广应用。

Objective：To investigate the clinical effect of Zoledronic Acid in postmenopausal osteoporosis and its effect on fracture rate.Method：100 patients with postmenopausal osteoporosis admitted from February 2016 to February 2017 were randomly divided into the control group and the observation group,50 cases in each group.Two groups were treated with Caltrate D Tablets and Calcitriol Soft Capsules.The control group combined with Alendronate treatment,the observation group combined with Zoledronic Acid treatment,visual analogue scale（VAS） scale to evaluate of two groups before and after treatment pain,the lumbar 1-4,femoral neck and Ward＇s bone mineral density（BMD） were measured by dual energy X-ray absorptiometry,the clinical efficacy and effect on fracture rate were compared between two groups.Result：The VAS score was compared between two groups before treatment,the difference was not statistically significant（P0.05）,the VAS scores in observation group werelower than that of control group for 1 months,3 months and 6 months after treatment（P0.05）,the lumbar 1-4,femoral neck and Ward＇s bone mineral density were compared between two groups before treatment,the difference was not statistically significant（P0.05）,the lumbar 1-4,femoral neck and Ward＇s bone mineral density of the observation group were higher than those of the control group for 1 month,3 months and 6 months after treatment（P0.05）,the incidence of fractures were compared between two groups for 1 month after treatment,the difference was not statistically significant（P0.05）,the incidence of fracture of the observation group were lower than those of the control group for 3 months and 6 months after treatment（P0.05）.Conclusion：The effect of Zoledronic Acid in postmenopausal osteoporosis patients is satisfactory,which is helpful to alleviate the pain,improve the bone mineral density and reduce the fracture rate.It is worthy of popularization and application.